SCHEMBL25904913

SCHEMBL25904913

CCCN(Nc1nc(SC)ncc1C(=O)OCC)C(=O)OC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.55
▸ ALDH1A1 P00352 5/20 0.54
▸ MAPT P10636 5/20 0.52
▸ LMNA P02545 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ NFKB2 Q00653 2/20 0.50
▸ RELA Q04206 2/20 0.50
▸ FOS P01100 1/20 0.50
▸ JUN P05412 1/20 0.50
▸ MAPK1 P28482 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ HPGD P15428 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20875448 0.92 SYK (0.57) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL20658731 0.91 ALDH1A1 (0.62) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL20875531 0.87 SYK (0.52) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL30310811 0.87 SYK (0.52) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL23126623 0.87 SYK (0.52) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL23126549 0.87 SYK (0.52) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL30421007 0.87 SYK (0.52) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL25031184 0.86 ALDH1A1 (0.57) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL20875506 0.86 SYK (0.52) SYKALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL25827991 0.85 SYK (0.51) SYKALDH1A1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234956-A1 METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC 2023-07-27 — — US disclosed
US-20230234956-A1 METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC 2023-07-27 — — US disclosed
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234956-A1 METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS WEE1, WEE2, CCNE1 SYK 4235/4885ALDH1A1 2247/4885MAPT 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback